Search
Zatonacaftor
go.drugbank.com/drugs/DB21625ExperimentalThe usage of the INN stem '-caftor' in the name indicates that Zatonacaftor is a Cystic fibrosis transmembrane regulator (CFTR) protein modulator, corrector, and amplifier. … Zatonacaftor is a small molecule drug.
Anifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigational[A237054] The design of early clinical trials of anti-interferon treatments such as anifrolumab, rontalizumab, and sifalimumab have come under criticism. … [A237054] The design of the clinical trials use different definitions of autoantibody positivity, making comparison between trials difficult; all trials involve large portions of patients also using corticosteroids
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193533,A193608] While some patients with this disorder develop PNs, this is considered relatively uncommon compared to other variants of NF-1. … [A193608] Use of selumetinib in this population has shown efficacy in shrinking associated tumours and is linked to other positive clinical outcomes.
Rilonacept
go.drugbank.com/drugs/DB06372ApprovedInvestigationalRilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) … Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1.
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigational[A234439] Prognosis is poor and more effective therapies are needed to treat relapsed/refractory cases and improve survival. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Diethylpropion
go.drugbank.com/drugs/DB00937ApprovedIllicitInvestigationalIt is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
Sucralfate
go.drugbank.com/drugs/DB00364ApprovedInvestigationalSucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis … It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076].
Categories: Aluminum ComplexProducts: Sulcrate Sus 100mg/mlNadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigationalCompared to [pembrolizumab], a smaller proportion of patients experienced grade 3-4 adverse events (4% vs 12.7%).[A255111] … It is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat.
Categories: Complex MixturesImelasomeran
go.drugbank.com/drugs/DB17090ApprovedInvestigationalImelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine.
Amifampridine
go.drugbank.com/drugs/DB11640ApprovedFirdapse (amifampridine) was formally approved by the US FDA for the treatment of adults with LEMS as recently as November of 2018 [L4819]. … It is currently used as the first-line symptomatic treatment for LEMS in adult patients and is ideally given as oral tablets in divided doses, three or four times a day.